Research
Novel Oral HAE Drug Measures Up to Injectable Options
The Brief
- A pivotal phase III trial found that prophylactic use of oral deucrictibant, a bradykinin B2 receptor antagonist, substantially reduced hereditary angioedema attacks.
- The primary endpoint was assessed for an extended-release formulation of deucrictibant.
- The results were reported by MedPage Today from ACAAI meeting coverage, which compares the oral drug with injectable options.
Why it matters
If confirmed, an oral prophylactic option could offer an alternative to injectable treatments for people with hereditary angioedema.
Who’s affected
- people with hereditary angioedema
- allergists and immunologists
- #hereditary angioedema
- #deucrictibant
- #clinical trial
- #drug development
- #immunology
(MedPage Today) -- Prophylactic use of the novel oral bradykinin B2 receptor antagonist deucrictibant substantially reduced hereditary angioedema (HAE) attacks, a pivotal phase III trial showed. For the primary endpoint, extended-release deucrictibant...